Welcome to our dedicated page for Recursion Pharmaceuticals SEC filings (Ticker: RXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Recursion Pharmaceuticals, Inc. filings document the regulatory record for a clinical-stage TechBio company advancing investigational medicines through an AI-native discovery and development platform. Its 8-K reports disclose operating results, financial condition, Regulation FD presentations, clinical and pipeline updates, partner milestones and material corporate events.
Proxy materials cover annual-meeting matters, director elections, executive compensation and governance practices. Other filings include leadership-transition disclosures, shelf-registration and prospectus-supplement records for Class A common stock, and capital-structure disclosures tied to shares issued under the Tempus master agreement.
Recursion Pharmaceuticals director Namandje Bumpus received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Bumpus directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation rather than open market transactions.
Dean Y. Li, Director at Recursion Pharmaceuticals (RXRX), reported significant insider transactions on June 18, 2025:
- Acquired 22,016 restricted stock units (RSUs) at $0, which vest on June 18, 2026 or before the 2026 Annual Meeting
- Received 44,031 stock options with exercise price of $5.11, expiring June 18, 2035
Li's total beneficial ownership includes:
- 1,234,618 shares held directly (including 1,132,815 shares transferred from GRAT)
- 1,980,029 shares held indirectly through various trusts: - 1,422,048 via Revocable Trust - 136,981 via GRAT - 421,000 via Family Trust
These grants were made automatically under the company's Outside Director Compensation Policy, subject to continued service.
Recursion Pharmaceuticals (RXRX) director Elaine D. Sun received new equity compensation grants on June 18, 2025, consisting of:
- 11,008 restricted stock units (RSUs) that will vest on the earlier of June 18, 2026, or the day before the 2026 Annual Meeting
- 22,016 stock options with an exercise price of $5.11, exercisable until June 18, 2035, vesting on the same schedule as the RSUs
Following these transactions, Sun directly owns 47,557 shares of Class A Common Stock and 22,016 stock options. Both grants are subject to continued service as a director. These equity awards were automatically granted according to the company's Outside Director Compensation Policy, representing standard board compensation arrangements.
Ben R Taylor, Chief Financial Officer of Recursion Pharmaceuticals (RXRX), reported multiple securities transactions and holdings in a Form 4 filing:
Key Transaction: On June 16, 2025, Taylor disposed of 7,057 shares of Class A Common Stock at $4.92 per share through a tax withholding transaction (F code) related to RSU settlement. Following this transaction, Taylor directly owns 823,134 shares.
Stock Option Holdings:
- 70,037 options at $7.25 (expires 2035)
- 740,686 options at $6.09 (expires 2034)
- 81,154 options at $0.14 (expires 2031)
- 92,748 options at $0.06 (expires 2031)
- 289,837 options at $0.04 (expires 2030)
All options have various vesting schedules ranging from monthly to annual installments, subject to continued service requirements.
Recursion Pharmaceuticals held its 2025 Annual Meeting on June 18, with stockholders voting on three key proposals. All proposals passed successfully.
Key outcomes include:
- Election of three Class I directors to serve until 2028: - Zachary Bogue (242.3M votes for) - Zavain Dar (203.3M votes for) - Robert Hershberg (233.5M votes for)
- Approval of executive compensation package with 239.9M votes in favor (97.4% of votes cast excluding abstentions)
- Ratification of PricewaterhouseCoopers LLP as independent auditor with 334.6M votes in favor (98.5% of votes cast excluding abstentions)
Notable was the significant support for Zachary Bogue and Robert Hershberg, while Zavain Dar received relatively more withheld votes. The executive compensation proposal received strong stockholder backing, demonstrating confidence in leadership compensation structures.